Apart from BDR, all have entered into voluntary licensing agreements with Gilead Science, US-based patent holder of this drug. Gilead said the timeline to get Remdesivir to Indian patients will depend on licensees and aprocess it does not control.
from Industry-Economic Times
Read The Rest:economictimes...